Rofecoxib-induced renal dysfunction in a patient with compensated cirrhosis and heart failure.
Ofran
Y
Y
Bursztyn
M
M
Ackerman
Z
Z
D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D005260:Female; D005355:Fibrosis; D006333:Heart Failure / Q000150:complications* / Q000473:pathology; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D007783:Lactones / Q000009:adverse effects*; D008565:Membrane Proteins; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology; D011451:Prostaglandin-Endoperoxide Synthases; D051437:Renal Insufficiency / Q000139:chemically induced* / Q000150:complications; D013450:Sulfones
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D007783:Lactones; D008565:Membrane Proteins; D013450:Sulfones; C116926:rofecoxib; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases